This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Relugolix for treating hormone-sensitive prostate cancer

Authoring team

Relugolix for treating hormone-sensitive prostate cancer

  • relugolix is an oral, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist licensed for androgen deprivation therapy (ADT) in adult patients with advanced hormone-sensitive prostate cancer (1,2)
  • mechanism of action:
    • competitively binds to pituitary GnRH receptors, rapidly inhibiting the release of luteinising hormone (LH) and follicle-stimulating hormone (FSH) and suppressing testosterone production (1,2)
    • unlike injectable luteinising hormone-releasing hormone (LHRH) agonists (e.g. leuprolide), relugolix achieves rapid testosterone suppression without an initial testosterone surge ("clinical flare"), avoiding the need for concomitant antiandrogen flare protection (1)

NICE guidance (TA995)

  • NICE recommends relugolix as an option for treating hormone-sensitive prostate cancer in adults (3):
    • with high-risk localised or locally advanced hormone-sensitive prostate cancer (3)
    • as neoadjuvant treatment before radiotherapy for high-risk localised or locally advanced hormone-sensitive prostate cancer (3)
    • when androgen deprivation therapy is suitable for relapsed or metastatic hormone-sensitive prostate cancer (3)
  • The NICE committee noted (3):
    • "...Clinical trial evidence suggests that relugolix is better at reducing testosterone to levels that stop cancer growth in the long term, and reduces the risk of serious cardiovascular events, compared with leuprolide..."

Clinical efficacy (HERO trial)

  • in the phase 3, open-label HERO trial (n = 930), men with advanced prostate cancer were randomised 2:1 to oral relugolix (360 mg loading dose on day 1, then 120 mg once daily) or depot leuprolide injections every 3 months for 48 weeks (1)
  • primary endpoint (sustained castration rate, testosterone <50 ng/dL from day 29 through 48 weeks):
    • achieved in 96.7% of patients receiving relugolix versus 88.8% receiving leuprolide (difference 7.9 percentage points; 95% CI 4.1 to 11.8; p < 0.001 for noninferiority and superiority) (1)
  • key secondary endpoints:
    • faster testosterone suppression: castrate levels (<50 ng/dL) achieved by day 4 in 56.0% with relugolix versus 0% with leuprolide (p < 0.001) (1)
    • faster testosterone recovery on cessation: in a subgroup followed after discontinuation (n = 184), mean testosterone levels at 90 days were 288.4 ng/dL with relugolix versus 58.6 ng/dL with leuprolide (54% vs 3% recovering to >=280 ng/dL) (1)

Cardiovascular safety profile and interpretation caveats

  • in a prespecified safety analysis of the HERO trial, the incidence of major adverse cardiovascular events (MACE; defined as nonfatal myocardial infarction, nonfatal stroke, and all-cause death) at 48 weeks was lower with relugolix than with leuprolide (1):
    • overall cohort: 2.9% (18/622) with relugolix versus 6.2% (19/308) with leuprolide (hazard ratio [HR] 0.46; 95% CI 0.24 to 0.88) (1)
    • subgroup with a prior history of MACE: 3.6% (3/84) with relugolix versus 17.8% (8/45) with leuprolide (1)
  • mechanistic imaging evidence (REVELUTION trial):
    • in a randomised trial of 62 men receiving pelvic radiotherapy plus ADT, leuprolide was associated with significantly greater 12-month progression in coronary artery total plaque volume (+68.9 mm3; 95% CI 23.2 to 114.5; p = 0.02) and noncalcified plaque volume (+64.5 mm3; 95% CI 31.6 to 97.3; p = 0.004) on serial CT coronary angiography compared with relugolix, suggesting a biological basis for differential vascular risk (4)
  • caution regarding claimed clinical cardiovascular benefits:
    • although NICE notes a reduced risk of serious cardiovascular events based on trial data (3) and imaging data suggest less noncalcified coronary plaque progression with relugolix (4), MACE in the HERO trial was assessed as a prespecified safety analysis rather than a primary endpoint; HERO was statistically powered to evaluate sustained testosterone suppression, not cardiovascular event reduction (1)
    • in HERO, the 48-week duration was relatively short for evaluating long-term cardiovascular morbidity and mortality, the absolute number of MACE events was small (37 events total across both arms), and subgroup analyses in men with prior MACE were exploratory (1,2)
    • similarly, the REVELUTION trial was small (n = 62) and powered only for surrogate CT plaque volumes rather than clinical MACE outcomes (4)
    • consequently, claimed reductions in clinical cardiovascular events over LHRH agonists should still be interpreted with considerable caution until confirmed in dedicated, adequately powered cardiovascular outcome trials (1,2,4)

Adverse effects and prescribing considerations

  • common adverse effects (occurring in >10% of patients in HERO): hot flushes (54.3%), fatigue (21.5%), constipation (12.2%), mild-to-moderate diarrhoea (12.2% vs 6.8% with leuprolide), and arthralgia (12.1%) (1)
  • practical considerations:
    • offers an oral alternative to depot injections, which may be advantageous where rapid testosterone recovery is desired (e.g. short-course neoadjuvant/adjuvant ADT with radiotherapy or intermittent ADT) (1,2)
    • requires daily adherence; unlike 3-monthly depot injections, treatment relies on consistent patient self-administration (1,2)

Reference:

  1. Shore ND, Saad F, Cookson MS, et al. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020;382(23):2187-2196. doi: 10.1056/NEJMoa2004325.
  2. Higgi A, Melvin C, Abdelrasheed A, Wilson K. Clinical Effectiveness of Oral Relugolix in Advanced Prostate Cancer: A Structured Review of Current Primary Research. Cureus. 2025;17(11):e97231. doi: 10.7759/cureus.97231.
  3. NICE (August 2024). Relugolix for treating hormone-sensitive prostate cancer (TA995).
  4. Patel SA, Yadalam AK, van Assen M, et al. Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial. JAMA Cardiol. 2026;11(5):459-463. doi: 10.1001/jamacardio.2025.5586.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page